On May 27, 2020, Novavax announced the acquisition of Praha Vaccines a.s., part of the Cyrus Poonawalla Group, in an all cash transaction of approximately $167 million. The acquisition included a biologics manufacturing facility and associated assets in Bohumil, Czech Republic.

The facility is expected to provide an annual capacity of over 1 billion doses of antigen starting in 2021 for NVX-CoV2373, Novavaxﾒ COVID-19 vaccine candidate. NVX-CoV2373 consists of a stable, prefusion protein antigen made using its proprietary nanoparticle technology and includes Novavaxﾒ proprietary Matrix-Mﾙ adjuvant.